BioSpace News Archive

Perceive Biotherapeutics announced the closing of a $78M Series B funding round led by Johnson & Johnson Innovation – JJDC, Inc., joining existing Series A investor Deerfield Management and new investors Braidwell LP, the Retinal Degeneration Fund, and Catalio Capital Management, LP.

OncoResponse announced that Clifford Stocks, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11 a.m. PST.

Lumen Bioscience provided a review of the company’s 2022 growth, including progress in its clinical development programs, GMP manufacturing expansion, and funding.

ElevateBio to Present at the 41 st Annual J.P. Morgan Healthcare Conference.

Ventus Therapeutics, Inc. announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 a.m. PST.

Laxxon Medical Corporation announced today their invitation to participate as a private company in the 25th Annual Needham Growth Conference at the Lotte New York Palace Hotel on January 10-12, 2023.

Affini-T Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference.

Acer Therapeutics Inc. today announced the initiation of two Phase 2, single-arm investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of the prostate.

Bellerophon Therapeutics, Inc. announced that it has entered into a license agreement for the development and commercialization of INOpulse® with Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China.

IMUNON, Inc., a clinical-stage drug development company, and The Wistar Institute, a global leader in biomedical research located in the heart of University City, Philadelphia, through its Vaccine & Immunotherapy Center, announce the signing of a first collaborative research agreement to research and develop new vaccine formulations utilizing IMUNON’s PLACCINE modality for the development of vaccines for infectious diseases.